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Immunocontraception targeting the zona pellucida shows promise as a safe, 
effective, and economically feasible method for controlling feral horse populations that 
roam public rangelands throughout the United States.  The efficacy of porcine zona 
pellucida (pZP) vaccines to generate high titers can be evaluated with an indirect 
immunofluorescence assay or a sperm binding assay using equine, bovine or porcine 
oocytes and sperm.    The objective of this research was to refine protocols for each of 
these assays that would yield high resolution results when comparing oocytes treated with 
high and low titer anti-pZP sera against various sets of control oocytes.   Dilutions of 
rabbit anti-horse IgG-fluorescein isothiocyanate were varied in an indirect 
immunofluorescence assay which quantified fluorescence emitted from the zona 
pellucida.  A dilution of 1:32 produced  greater fluorescence intensity from oocytes 
treated with anti-pZP serum than control oocytes.  Fluorescence intensity of oocytes  
 
treated with the  1:32 dilution also varied significantly by the titer level, high or low, of 
anti-pZP serum used.  A sperm binding inhibition assay was performed using a longer 
incubation time for sperm binding than had been previously documented.  However, this 
modification did not produce any higher resolution than results reported in previous 
studies.   
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REVIEW OF THE LITERATURE  
 
 
 
Wild Horse Population Problem 
 
 
  Public range lands in the United States are home to tens of thousands of feral 
horses and burros, believed to be descendants  of Spanish horses brought to the New 
World in the 1500’s, who interbred with released or escaped domestic horses.  Through 
the 1900s, these animals were unprotected, and many were rounded up to be used as 
rodeo stock or slaughtered for meat.  By the 1950’s, there were fewer than 10,000 
remaining, and public attention was brought to the diminishing numbers, as well as the 
inhumane methods used by private parties to gather, transport and slaughter these horses.  
Activists began to pressure the federal government to create laws protecting these 
animals, and in 1971 the Wild Free-Roaming Horse and Burro Act passed (BLM, 2012).  
It provided federal protection to herds on public lands, and charged the Secretary of the 
Interior with managing them.  It is now a felony to remove these horses, harass, or kill 
them (BLM, 2006).   
Without natural or human predators, however, feral horse populations can 
increase rapidly.  On many rangeland areas they are at such high densities they cause 
damage to the ecosystem, compete with wildlife and cattle, and in extreme cases 2 
 
experience severe food shortages themselves.  In effort to control the population, the 
Bureau of Land Management (BLM, 2012) estimates the number of horses that can be 
supported on individual public rangelands throughout the country without causing 
excessive damage to the ecosystem, termed the Appropriate Management Level, and 
removes all animals in excess of this number.  These animals are kept in holding areas 
while the BLM attempts to re-home them through the Adopt-A-Horse Program.  Initially, 
BLM could not sell or destroy un-adoptable healthy animals.  A 2004 amendment 
allowed for certain un-adoptable animals to be sold indiscriminately, however, BLM has 
not sold any of these to kill buyers for fear of public relations repercussions (BLM, 
2012).   
According to BLM (2012) there are currently 37,300 free roaming, feral horses, 
11,000 in excess of BLM’s Appropriate Management Level.  There are an additional 
46,500 animals in BLM’s long term and short term holding pens.  The number of horses 
adopted out is declining, and in the 2012 fiscal year, only 2,589 animals were adopted of 
the 8,285 gathered.  The BLM is running out of holding capacity for these horses, as well 
as funds to pay for their care.  It is clear another strategy is necessary to control these 
populations.  Reproductive management to curb population growth appears to be the best 
solution (Garrot et al., 1991; 1992).   
 
 
Methods of Reproductive Control 
 
 
  A wide variety of options have been studied as contraceptive methods for wild 
horses.  However, the ideal contraceptive for wild horses must meet a number of 3 
 
requirements, including long lasting and highly effective contraception from a single 
application, ability for remote delivery, safety for animals farther down in the food chain, 
and safety for target animals, including pregnant mares (Kirkpatrick and Turner, 1991). 
  Herd stallion sterilization had been suggested as a means of fertility control, 
however this would be ineffective and impractical for several reasons.  Jannet et al. 
(2008) showed that vaccination against the reproductive hormone gonadotropin releasing 
hormone (GnRH) would be effective as contraception, but would cause suppression of 
mating behavior and secondary sex characteristics.  Without secondary sex traits, 
dominant stallions would fail to keep their breeding bands together, and the social 
structure of feral horses would be disrupted (Kirkpatrick et al., 2011).  Surgically 
vasectomizing stallions would cause infertility without behavioral changes, however this 
process carries the high risks and cost of capture, immobilization, and surgery.  
Furthermore, Asa (1999) found that herds with a vasectomized lead stallion will still 
experience 17% to 33% conception rates, due to sneak breedings by bachelor stallions.  
Instead, focus has been on finding a contraceptive method for mares. 
  Successful contraception has been observed using an intra-uterine device (IUD) in 
mares.  Plotka et al. (1992) found that IUDs containing progesterone and 
ethinyloestradiol provided high contraception rates in feral mares over the three year 
study.  However, it is necessary to use synthetic hormones because animals rapidly 
metabolize native hormones, such as progesterone and estradiol (Kirkpatrick et al, 1993).  
The possibility of these synthetic hormones being passed to animals farther down the 
food chain may make it difficult or impossible for these IUDs to be approved by the Food 
and Drug Administration and the Environmental Protection Agency (Kirkpatrick et al., 4 
 
1993).  The cost of capture and immobilization also makes this method impractical 
compared to methods for which remote delivery is possible.   
  Immunocontraception is a more practical method for fertility control than 
hormonally based IUDs because it can be delivered remotely (Willis et al., 1994).  
Additionally, steroid hormones in the tissue of target animals could have a negative effect 
on predators, while proteins from an immunocontraceptive would be deactivated in the 
stomach of non-target animals should they be ingested orally (Warren et al., 1993).  
Immunocontraception causes infertility by introducing an antigen to trigger an active 
immune response in the target animal against some molecule necessary for reproduction 
(Kirkpatrick and Turner, 1991) 
GnRH has been studied as a possible target for immunocontraception in mares.  
GnRH is a hypothalamic hormone that acts on the pars distalis of the pituitary gland to 
cause secretion of the two hormones that control ovulation, luteinizing hormone (LH) and 
follicle stimulating hormone (FSH) (Senger, 2003).  Immunocontraceptive vaccines 
combine GnRH conjugated with a larger protein and an adjuvant.  Antibodies are 
generated which bind GnRH to prevent stimulation of the pituitary gland and 
consequently suppress LH and FSH secretion.   
Killian et al. (2004) showed immunocontraceptives targeting GnRH to be an 
effective method of contraception and somewhat effective long term.   Fifteen mares 
treated with a single application of GonaCon™ GnRH immunocontraceptive were 
monitored over a four year period for contraception and antibody titer levels.  Antibody 
levels declined over time, and contraception rates while exposed to a fertile stallion were 5 
 
94%, 60%, 60% and 40% respectively over the four years.  Although GnRH vaccines 
show promise, Miller et al. (2008) believes that current GnRH vaccines could not be 
considered highly effective long term.  Zona pellucida based immunocontraceptives show 
promise to have the safety and remote delivery advantages of GnRH vaccinations, but 
with higher and longer lasting efficacy (Killian et al., 2004).   
 
 
The Zona Pellucida as an Immunocontraceptive Target 
 
 
  The zona pellucida (ZP) is an acellular glycoprotein matrix that forms between 
the membrana granulosa and the oocyte during the second stage of folliculogenesis 
(Senger, 2003).  It provides protection for the oocyte and early embryo, is involved with 
sperm recognition, binding and penetration, prevents polyspermy, and initiates the 
acrosome reaction (Wassarman, 2008).  The ZP of most mammalian species is comprised 
of three glycoproteins, termed ZP1, ZP2, and ZP3 (Wassarman, 2008).  ZP3 is 
responsible for sperm recognition and binding, and induction of the acrosome reaction 
(Wassarman, 2008).  Porcine ZP has small amounts of ZP2, but the pZP3 family contains 
two immunologically and structurally distinct glycoproteins, ZP3α and ZP3β (Sacco, 
1989).  Sacco et al. (1989) showed that pZP3α is involved in sperm binding, but ZP3β is 
not.   
  The ZP is an ideal target for immunocontraception because it is involved in sperm 
binding, and is therefore essential for fertilization.  Injection of adjuvanted porcine ZP3 
(pZP) will generate an active immune response against the female’s own ZP3, and cause 
contraception (Barber and Fayer-Hoskens, 2000a).  Porcine ZP immunocontraceptive 6 
 
shows promise as a safe and feasible fertility control method for feral horses.  Risk of 
toxic side effects is low because the ZP is specific to the ovary, meaning anti-ZP 
antibodies are unlikely to react with somatic tissue in other parts of the body (Barber and 
Fayer-Hosken, 2000b).  Barber and Fayer-Hoskens (2000b) also showed that adjuvanted 
pZP is not toxic to non-target animals when ingested orally, and does not influence their 
reproductive abilities.  Because antigenic determinants on the ZP are shared across 
species, an immune response can be generated in horses using pZP, which can be 
obtained inexpensively and in large quantities (Yurewicz et al., 1987). 
  Vaccination with pZP3 has been shown in multiple studies to cause the mare to 
generate antibodies against the ZP and cause contraception.  Liu et al. (1989) performed 
the first trial of pZP vaccination in horses.  Fourteen fertile mares were given four 
injections of heat solubilized pZP at two to four week intervals and a booster six to ten 
months later.  Aluminum hydroxide gel was initially used as an adjuvant, and replaced 
with Freund’s adjuvant due to low efficacy.  Contraception for at least 7 months was seen 
in 86% of mares.   
   Kirkpatrick et al. (1990; 1991; 1992) studied pZP vaccination using feral mares 
on Maryland’s Assateague Island.  They gave an initial injection of pZP with Freund’s 
Complete Adjuvant (FCA), followed by two booster injections of pZP with Freund’s 
Incomplete Adjuvant (FIA).  Two annual booster vaccinations were given and foaling 
rates of treated, control and untreated mares were monitored over the three years 
following the initial injection.  The first year, a 50% decrease in foaling was reported, the 
second year foaling rate decreased to 7%, compared to 44% and 50% in control and 
untreated mares, and by the third year 100% contraception was observed (Kirkpatrick et 7 
 
al., 1990; 1991; 1992).  This study also revealed that pZP had no harmful effects on 
existing pregnancies, however a few mares did develop injection site reactions 
(Kirkpatrick et al., 1990).  Willis et al. (1994) showed that remote delivery is possible 
with pZP vaccines by administering an initial vaccine and a booster of a pZP formulation 
with a biobullet to six mares.  Contraception for two years was observed in all six mares 
(Willis et al. (1994).  
  To date the only pZP preparation that can provide long term contraception from a 
single dose is SpayVac™ (SpayVac).  SpayVac utilizes liposome encapsulation of ZP 
antigens to provide a boosting effect after the injection (Maudlin et al., 2007).  Killian et 
al. (2008) tested SpayVac on a group of 12 mares.  After a single injection of SpayVac, 
contraception rates of 100%, 83%, 83% and 83% were observed over the next four years, 
respectively (Killian et al., 2008).   
 
 
In Vitro Methods for Evaluating Efficacy  
 
 
  Liu et al. (1989) used two in vitro methods for evaluating the efficacy of the pZP 
vaccine tested.  An indirect immunofluorescence assay was used to determine the ability 
of anti-ZP antibodies to bind to the ZP of equine and porcine oocytes.  Oocytes were 
collected, and incubated first in antiserum from mares inoculated with pZP vaccine, then 
in fluorescein isothiocyanate (FITC)-conjugated rabbit anti-horse IgG diluted 1:10 (Liu et 
al., 1989).  Equine anti-serum was shown to bind with the ZP of equine and porcine 
oocytes as determined by quantifying fluorescence using an Olympus B2-2 microscope.   8 
 
  Liu et al. (1989) used sperm binding inhibition assays as a second method for in 
vitro assessment.  Equine, porcine, and bovine oocytes were incubated in equine anti-pZP 
serum, and washed three times by centrifugation.  Treated oocytes were incubated 
overnight in capacitated equine or porcine sperm, and the number of sperm tightly bound 
to each oocyte was counted.  Sperm binding inhibition was observed in porcine and 
bovine oocytes incubated with pZP anti-sera as compared to oocytes incubated with 
control sera, although results were not obtained for sperm binding to horse oocytes due to 
inconsistent controls.  The results of these two assays are consistent with the high 
contraceptive rates seen in mares immunized with the pZP preparation.  
  VanderVoort (1995) also used a sperm binding inhibition assay to test the efficacy 
of various recombinant ZP proteins as immunocontraceptives in monkeys.  Oocytes were 
incubated with control sera, or anti-sera against various ZP preparations for either four or 
24 hours.  After incubation of treated oocytes with sperm, the number of sperm bound to 
each oocyte was counted.  Significant differences in sperm binding between the control 
oocytes, and those treated with a preparation of the 55 kD ZP protein, were seen for both 
four and 24 hour treatment incubation groups.  VanderVoort (1995) used this information 
in his conclusion that the 55 kD ZP protein serves as the sperm receptor.   
  Bartell (2011) evaluated the efficacy of the pZP preparation SpayVac as an 
immunocontraceptive in horses using both an indirect immunofluorescence assay with 
bovine oocytes and a sperm binding inhibition assay with bovine oocytes and sperm.  To 
evaluate anti-pZP binding, oocytes were incubated in Dulbecco’s phosphate buffered 
saline (DPBS), or 0.05% pooled sera from control, pre-immune, or high anti-pZP titer 
mares, washed, and incubated with FITC-conjugated rabbit anti-horse IgG at a 9 
 
concentration of 1:64 for one hour.  Oocytes treated with high titer anti-pZP sera 
fluoresced with significantly higher intensity than oocytes treated with DPBS or pre-
immune sera, however no significant difference in fluorescence was observed between 
oocytes treated with control and high titer anti-pZP sera.   
  Bartell (2011) also evaluated inhibition of bovine sperm binding to bovine oocyte 
ZP by anti-pZP sera. Inhibition of sperm binding was evaluated by treating bovine 
oocytes with DPBS, or 0.05% pooled sera from control, pre-immune, or high anti-pZP  
titer mares for two hours, washing oocytes, then incubating oocytes with bovine sperm 
for 4 hours.  The number of sperm tightly bound to each oocyte was counted.  Number of 
sperm bound to oocytes treated with high titer anti-pZP serum was significantly lower 
than the number of sperm bound to oocytes treated with pre-immune serum or DPBS, but 
not significantly different from the number of sperm bound to oocytes treated with 
control serum.    
  In both of the assays used by Bartell (2011), statistically significant differences 
between high titer anti-pZP and control sera could not be detected. Sera collected from 
control mares have no pZP titers so a precise in vitro assay should be able to confidently 
discriminate between high titer anti-pZP and control sera. Therefore, the objective of this 
research was to refine the protocols used by Bartell (2011) to develop more precise assay 
conditions where obvious differences between high titer anti-pZP and control sera could 
be detected with statistical significance.   
   10 
 
MATERIALS AND METHODS 
 
 
 
Indirect Immunofluorescence Assay 
 
 
  Bovine ovaries were obtained from a local abattoir, frozen and thawed to room 
temperature before use.  To collect oocytes, ovaries were ground gently in a tissue 
homogenizer with DPBS.  The resulting liquid and ground tissue were strained through a 
gauze filter and a Teflon screen.  This grinding and filtration process was repeated three 
times, so that for the final filtration, the ovarian tissue was completely homogenized.  The 
Teflon screen was inverted over a collection dish, and oocytes were recovered from the 
surface by rinsing thoroughly with a jetted stream of DPBS.  The collection dish was 
searched using a dissecting microscope at 20X magnification, and oocytes without 
cumulus cells were removed into DPBS with 0.5% bovine serum albumin (BSA).   
  Recovered oocytes were fixed in a 2% paraformaldehyde in DPBS solution for at 
least one hour and washed through three 50 µL microdrops of DPBS with 0.5% BSA 
under paraffin oil.  Oocytes were blocked for one hour in 50 µL microdrops of DPBS 
with 5% heat treated fetal calf serum (HTFCS), and then washed through three 
microdrops of DPBS with 0.5% BSA.  Blocked oocytes were separated into 5 treatment 
groups, and treated for 1 hour in 50 µL microdrops of DBPS, or DPBS with 1:200 
dilutions of pooled sera from pre-immune, control, or  low or high pZP titer mares 
vaccinated with SpayVac.  Oocytes were washed through three microdrops of DPBS with 
0.5% BSA, incubated for 1 hour in FITC-conjugated rabbit anti-horse IgG at dilutions of 
1:32, 1:40, 1:64 and 1:128. and washed again through three microdrops of DPBS and 11 
 
0.5% BSA.  Fluorescence intensity was evaluated using epifluorescence on a Leitz 
inverted stage phase contrast microscope with a FITC filter and quantified using a Leitz 
photometer. 
  The DPBS group was not repeated in trials with 1:40 and 1:128 concentrations of 
FITC-conjugated rabbit anti-horse IgG, as the trials with 1:32 and 1:64 dilutions were 
sufficient to show significantly low anti-pZP binding.  The low titer group was not used 
in the trial with the 1:128 dilution of FITC-conjugated rabbit anti-horse IgG, as the first 
three trials were sufficient to show a significant difference in anti-pZP binding between  
low and high titer groups.   
 
Sperm Binding Inhibition Assay 
 
 
  Bovine oocytes were collected using the process described above.  Recovered 
oocytes were vortexed for 15 seconds at high speed to remove cumulus cells.  Oocytes 
were washed through three 50 µL microdrops of DBPS with 0.5% BSA, fixed for two 
hours in 2% paraformaldehyde, and washed through three microdrops of Sperm TALP 
(Parrish et al., 1988),  Oocytes were incubated for two hours in one of five treatments: 
DPBS, or  1:200 dilutions of pooled sera from pre-immune, control low or high titer anti-
pZP sera from mares incubated with SpayVac.  Oocytes were washed through four 
microdrops of sperm TALP.  Frozen bovine semen in a 0.5 cc straw was thawed in a 
water bath at 37°C for 45 seconds.  Motile sperm were selected using the sperm swim-up 
procedure described by Parrish et al. (1988) and suspended in Sperm TALP.  Oocytes 
were added to 40 µL microdrops of Sperm TALP containing 25,000 sperm, and 12 
 
incubated overnight at 39°C in a humidified atmosphere of 5% CO2 in air.  Sperm and 
oocytes were placed in a microcentrifuge tube with 100 L of DPBS-BSA and vortexed 
at a low fixed speed for 15 seconds to remove loosely bound sperm from oocytes. Sperm-
bound oocytes were recovered from the microcentrifuge tube, washed through three 
drops of DPBS-BSA, and fixed in paraformaldehyde for at least one hour.  Fixed oocytes 
were washed through four microdrops of DPBS-BSA, and incubated for 10 min in the 
dark with 1% Hoechst 33324 in 25% ethanol in sodium citrate dehydrate solution.  
Oocytes were washed through three microdrops of DPBS-BSA, and the number of sperm 
tightly bound to each oocyte was counted using epifluorescence on a Leitz inverted stage-
phase contrast microscope at 200X magnification.      
 
   13 
 
RESULTS 
 
 
 
Indirect Immunofluorescence Assay 
 
 
Fluorescence intensity was higher (P < 0.05) for oocytes treated with high 
compared to low titer anti-pZP sera when 1:32, 1:40, and 1:64 dilutions of FITC-
conjugated rabbit anti-horse IgG were used (Figures 1 and 2).  Oocytes treated with sera 
from mares vaccinated  with SpayVac fluoresced significantly more (P < 0.05) intensely 
than oocytes treated with sera from control or pre-immune mares, or  DPBS, for all 
concentrations of FITC-conjugated rabbit anti-horse IgG (Figures 1, 2, and 3).   
Oocytes treated with the 1:32 dilution of FITC-conjugated rabbit anti-horse IgG 
fluoresced more (P<0.05) intensely than oocytes treated with all lower concentrations.  
No significant difference was observed between oocytes treated with 1:40 and 1:64 
dilutions of FITC-conjugated rabbit anti-horse IgG.  Oocytes treated with a 1:128 dilution 
of FITC-conjugated rabbit anti-horse IgG fluoresced less (P<0.05) intensely than oocytes 
treated with all higher concentrations.   
 
 
 
 14 
 
 
Figure 1. Mean relative fluorescence for bovine oocytes incubated in DPBS or pooled 
sera recovered from pre-immune, control, low or high pZP titer mares and exposed to 
rabbit anti-horse IgG-FITC conjugate at 1:32 or 1:64 dilutions. 
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Figure 2. Mean relative fluorescence for bovine oocytes incubated in pooled sera 
recovered from pre-immune, control, low or high pZP titer mares and exposed to rabbit 
anti-horse IgG-FITC conjugate at 1:32, 1:40, or 1:64 dilutions. 
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Figure 3. Mean relative fluorescence for bovine oocytes incubated in pooled sera 
recovered from pre-immune, control or high pZP titer mares and exposed to rabbit anti-
horse IgG-FITC conjugate at 1:32, 1:40, 1:64, or 1:128 dilutions 
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Sperm Binding Inhibition Assay 
 
 
Sperm binding was lower (P<0.05) on oocytes treated with anti-pZP sera from 
mares treated with SpayVac than sera from pre-immune mares (Figure 4).  No significant 
difference  was observed between oocytes treated with DPBS,  control or high titer sera, 
or between oocytes treated with DPBS, control or pre-immune sera, although a higher 
mean number of sperm bound was observed on oocytes treated with DPBS and control 
sera than high titer sera.   
 
Figure 4. Mean number of bovine sperm bound to bovine oocytes following incubation in 
DPBS or pooled sera recovered from pre-immune, control, or high pZP titer mares. 
a,b Means without common superscripts differ (P<0.05). 
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DISCUSSION 
 
 
 
Indirect Immunofluorescence Assays  
 
 
  Bartell (2011) showed that indirect immunofluorescence assays will confirm anti-
pZP binding in bovine oocytes, but significant differences in fluorescence intensity were 
only observed between anti-pZP serum treated oocytes, and pre-immune serum and 
DPBS treated oocytes.  In this study, significantly higher florescence intensity was 
observed in oocytes treated with anti-pZP serum compared to oocytes treated with DPBS, 
control serum or pre-immune serum.  Florescence intensity was also shown to reflect the 
titer level of anti-pZP sera used.  Ocytes treated with high titer anti-pZP serum fluoresced 
at a higher intensity than oocytes treated with low titer anti-pZP serum.  It was also 
shown that florescence intensity increases with higher concentrations of rabbit anti-horse 
FITC.  Rabbit anti-horse FITC concentration of 1:32 produced results with the most 
distinction between florescence intensity of oocytes treated with control, and high and 
low titer anti-pZP sera.   
 
 
Sperm Binding Inhibition Assay 
 
 
  Bartell (2011) reported significantly lower sperm binding in oocytes treated with 
high titer anti-pZP serum than oocytes treated with pre-immune serum and DPBS, but did 
not find a significant difference between oocytes treated with high titer anti-pZP serum 
and control serum.  It was hypothesized that by extending the incubation of oocytes with 19 
 
sperm from four hours to overnight, results could be obtained that showed a significant 
difference between oocytes treated with high titer anti-pZP serum and control serum.  
Although the difference between high titer serum, and pre-immune serum and DPBS seen 
in Bartell (2011) was replicated in this study, no significant difference was seen between 
high titer and control sera. Extending the sperm-oocyte incubation period did not improve 
precision in the sperm binding assay.     20 
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